NO331083B1 - Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati - Google Patents

Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati

Info

Publication number
NO331083B1
NO331083B1 NO20033228A NO20033228A NO331083B1 NO 331083 B1 NO331083 B1 NO 331083B1 NO 20033228 A NO20033228 A NO 20033228A NO 20033228 A NO20033228 A NO 20033228A NO 331083 B1 NO331083 B1 NO 331083B1
Authority
NO
Norway
Prior art keywords
inhibitor
expression vector
cardiomyopathy
inducing
enhancing
Prior art date
Application number
NO20033228A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033228L (no
NO20033228D0 (no
Inventor
Charles Dinarello
Yolande Chvatchko
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20033228D0 publication Critical patent/NO20033228D0/no
Publication of NO20033228L publication Critical patent/NO20033228L/no
Publication of NO331083B1 publication Critical patent/NO331083B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20033228A 2001-01-29 2003-07-16 Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati NO331083B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (3)

Publication Number Publication Date
NO20033228D0 NO20033228D0 (no) 2003-07-16
NO20033228L NO20033228L (no) 2003-09-26
NO331083B1 true NO331083B1 (no) 2011-10-03

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033228A NO331083B1 (no) 2001-01-29 2003-07-16 Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati

Country Status (32)

Country Link
US (1) US20040234523A1 (pl)
EP (1) EP1355668B1 (pl)
JP (2) JP4860897B2 (pl)
KR (1) KR100857376B1 (pl)
CN (1) CN1326562C (pl)
AR (1) AR032422A1 (pl)
AT (1) ATE380558T1 (pl)
BG (1) BG66483B1 (pl)
BR (1) BR0206819A (pl)
CA (1) CA2435466C (pl)
CY (1) CY1107203T1 (pl)
CZ (1) CZ305653B6 (pl)
DE (1) DE60224004T2 (pl)
DK (1) DK1355668T3 (pl)
EA (2) EA010180B1 (pl)
EE (1) EE05534B1 (pl)
ES (1) ES2295332T3 (pl)
HK (1) HK1062810A1 (pl)
HR (1) HRP20030609A2 (pl)
HU (1) HU229164B1 (pl)
IL (2) IL157024A0 (pl)
ME (1) ME00549B (pl)
MX (1) MXPA03006776A (pl)
NO (1) NO331083B1 (pl)
PL (1) PL213568B1 (pl)
PT (1) PT1355668E (pl)
RS (1) RS51125B (pl)
SI (1) SI1355668T1 (pl)
SK (1) SK287620B6 (pl)
UA (1) UA80676C2 (pl)
WO (1) WO2002060479A1 (pl)
ZA (1) ZA200305439B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257585A2 (en) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2384241T3 (es) 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
AU2014317035B2 (en) * 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
WO1998010778A1 (en) * 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
WO1998024804A2 (en) * 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
ES2146192T1 (es) * 1997-03-18 2000-08-01 Basf Ag Metodo y composiciones para modular la sensibilidad a los corticosteroides.
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
ATE336480T1 (de) * 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
BR0009610A (pt) * 1999-04-09 2002-02-13 Cytovia Inc Inibidores de caspase e uso dos mesmos
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
EA007014B1 (ru) * 2000-05-05 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Применение il-18 в качестве диагностического маркера
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
BG108128A (bg) 2004-11-30
CZ305653B6 (cs) 2016-01-27
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
HUP0303306A3 (en) 2005-12-28
HRP20030609A2 (en) 2005-06-30
PL213568B1 (pl) 2013-03-29
MXPA03006776A (es) 2003-10-24
CN1326562C (zh) 2007-07-18
DK1355668T3 (da) 2008-05-05
HU229164B1 (en) 2013-09-30
EE05534B1 (et) 2012-04-16
RS51125B (sr) 2010-10-31
CZ20032335A3 (en) 2004-07-14
IL157024A0 (en) 2004-02-08
JP2009102354A (ja) 2009-05-14
EE200300328A (et) 2003-10-15
EA200300844A1 (ru) 2003-12-25
JP2004522748A (ja) 2004-07-29
PL366802A1 (pl) 2005-02-07
EP1355668A1 (en) 2003-10-29
EP1355668B1 (en) 2007-12-12
BG66483B1 (bg) 2015-03-31
ME00549B (me) 2011-10-10
AR032422A1 (es) 2003-11-05
SK10892003A3 (sk) 2004-02-03
CA2435466A1 (en) 2002-08-08
SI1355668T1 (sl) 2008-06-30
JP4860897B2 (ja) 2012-01-25
PT1355668E (pt) 2008-01-04
CY1107203T1 (el) 2012-11-21
IL157024A (en) 2014-02-27
ATE380558T1 (de) 2007-12-15
US20040234523A1 (en) 2004-11-25
EA200501549A1 (ru) 2006-04-28
HUP0303306A2 (hu) 2004-01-28
ES2295332T3 (es) 2008-04-16
YU57803A (sh) 2006-05-25
EA006767B1 (ru) 2006-04-28
WO2002060479A1 (en) 2002-08-08
HK1062810A1 (en) 2004-11-26
KR100857376B1 (ko) 2008-09-05
DE60224004D1 (de) 2008-01-24
EA010180B1 (ru) 2008-06-30
CA2435466C (en) 2012-04-03
BR0206819A (pt) 2004-02-03
NO20033228L (no) 2003-09-26
CN1499982A (zh) 2004-05-26
ZA200305439B (en) 2004-07-15
NO20033228D0 (no) 2003-07-16
UA80676C2 (en) 2007-10-25
DE60224004T2 (de) 2009-07-23

Similar Documents

Publication Publication Date Title
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
DK1373191T3 (da) Acylerede indanylaminer og deres anvendelse som lægemidler
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
DK2336167T3 (da) MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
IS2485B (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
DK1516053T3 (da) Xylanaser, nucleinsyrer, som koder herfor, og fremgangsmåder til at fremstille og benytte disse
NO331083B1 (no) Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20042478L (no) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
NO20044665L (no) Renzoksazin-derivater som 5-HT6-modulatorer og anvendelser derav
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1525193T3 (da) Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
NO20053588L (no) Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
DK1353912T3 (da) 2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired